December 8, 2025BloodOpen Access

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Single-arm trial reveals 92.5% overall response rate in relapsed T-cell lymphomas, suggesting high tolerability of CD7 CAR T cells.

92.5% overall response rate observed at one month after infusion in T-cell lymphoma patients, with promising long-term outcomes.
Phase I study included 40 patients, where 80% experienced cytokine release syndrome and 77.5% developed neutropenia.
Evaluation of CD7 CAR T-cell therapy was conducted through a detailed dose-escalation study assessing safety and efficacy metrics.
Significant improvements seen in progression-free survival rates highlight the potential of CD7 CAR T-cell therapy for challenging cases.

Yang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Single-arm trial reveals 92.5% overall response rate in relapsed T-cell lymphomas, suggesting high tolerability of CD7 CAR T cells.

92.5% overall response rate observed at one month after infusion in T-cell lymphoma patients, with promising long-term outcomes.
Phase I study included 40 patients, where 80% experienced cytokine release syndrome and 77.5% developed neutropenia.
Evaluation of CD7 CAR T-cell therapy was conducted through a detailed dose-escalation study assessing safety and efficacy metrics.
Significant improvements seen in progression-free survival rates highlight the potential of CD7 CAR T-cell therapy for challenging cases.

Yang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark